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E-mail address: joakim.lundeberg@scilifelab.se (J.Personalized cancer treatment requires molecular characterization of individual tumor biopsies. These
samples are frequently only available in limited quantities hampering genomic analysis. Several whole
genome ampliﬁcation (WGA) protocols have been developed with reported varying representation of
genomic regions post ampliﬁcation. In this study we investigate region dropout using a u29 polymerase
basedWGA approach. DNA from 123 lung cancers specimens and corresponding normal tissue were used
and evaluated by Sanger sequencing of the p53 exons 5–8. To enable comparative analysis of this scarce
material, WGA samples were compared with unampliﬁed material using a pooling strategy of the 123
samples. In addition, a more detailed analysis of exon 7 amplicons were performed followed by extensive
cloning and Sanger sequencing. Interestingly, by comparing data from the pooled samples to the individ-
ually sequenced exon 7, we demonstrate that mutations are more easily recovered from WGA pools and
this was also supported by simulations of different sequencing coverage. Overall this data indicate a lim-
ited random loss of genomic regions supporting the use of whole genome ampliﬁcation for genomic
analysis.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
DNA based diagnostics are becoming increasingly important in
cancer treatment and prevention, and the increasing knowledge is
leading to more tailored analysis of biomarkers. Ever since the dis-
covery of the tumor suppressor gene p53 in 1979 by Arnold Levine
[1], there have been numerous approaches to investigating this
particularly interesting gene in various cancers [2]. It is activated
by DNA damage and acts as a master regulator for gene networks
involved in DNA repair, cell cycle arrest and apoptosis. There are
several studies reporting the clinical associations between muta-
tions in p53 and various forms of cancers (reviewed in [3,4]),
including lung cancer. For example, the prevalence of somatic
mutation association in the p53 gene ranges from 50% in non-small
cell lung cancer (NSCLC) to 80% in small cell lung cancer (SCLC)
[5,6]. The role of the high frequency of p53 mutations in lung can-Y-NC-ND license. 
aboratory, School of Biotech-
e of Technology, Stockholm,
Lundeberg).cer is still under investigation, in particular its relation the overall
genome mutation patterns have been presented after whole gen-
ome sequencing of a small cell lung cancer cell line [7].
To facilitate the application and use of both broad genomic
tools, such as massive parallel sequencing, and more focused stud-
ies of biomarker genes on small biopsies and tumor samples, in-
creased amount of genomic DNA is commonly required. Robust
methods are therefore needed to amplify the genomic material
from scarce samples without compromising the quality or intro-
ducing signiﬁcant bias. PCR-based methods for whole genome
ampliﬁcation (WGA) include primer extension pre-ampliﬁcation
(PEP), improved-PEP (I-PEP), degenerate oligonucleotide primed
PCR (DOP-PCR) and ligation mediated PCR [8–10]. Additionally,
there are several non-PCR based methods such as strand displace-
ment ampliﬁcation (SDA), T7-based linear ampliﬁcation of DNA
(TLAD) and isothermal multiple displacement ampliﬁcation
(MDA) (reviewed in [11]). MDA is based on the u29 polymerase
enzyme, derived from Bacillus subtilis bacteriophage.
Ampliﬁcation bias and allelic drop-out are issues in current
whole genome ampliﬁcation methods when starting from low in-
put amounts of DNA. Different laboratories have reported their
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product length of the PCR based methods is a limitation for some
applications and this together with the ease of use of the MDA ap-
proach makes several research groups focus on MDA [15–17].
In this study, we investigate the use of a u29 polymerase based
WGA strategy by Sanger sequencing of amplicons, as an approach
to analyze scarce lung cancer tumor samples. In particular we fo-
cused on the exons 5–8 in p53 tumor suppressor gene in individual
normal and tumor samples. The results can serve as a valuable
guide for projects requiring whole genome ampliﬁcation starting
from minute amounts of DNA.2. Materials and methods
2.1. Samples
A total of 123 patients diagnosed with non-small cell lung can-
cer or small cell lung cancer were used in this study obtained from
Institut de Gustave Roussy and Institut Mutualiste Montsouris
(IMM), Paris. The homogeneity of tumor cells was according to
microscopical examination >70%. Tumor and corresponding nor-
mal genomic DNA was extracted by conventional means. Genomic
DNA concentration spanned from 2 to 41.6 ng/ul. Samples were
used in accordance with the ethical guidelines of CHEMORES con-
sortium (http://www.chemores.org) with the purpose of generat-
ing a systems biology database to study resistance to
chemotherapy.
2.2. Whole genome ampliﬁcation
The Illustra GenomiPhi V2 DNA ampliﬁcation kit (GE Health-
care, Waukesha, Wisconsin) with random hexamer primers was
used to amplifying the DNA according to manufacturer’s instruc-
tions [18,19]. To conﬁrm that the WGA reaction was successful
samples was subjected to gel electrophoresis (data not shown).
2.3. PCR of individual samples
Four separate PCR reactions were performed for eachWGA tem-
plate to amplify the p53 exons 5–8. The AmpliTaq Gold kit (Applied
Biosystems, Foster City, California) and FastStart HiFi PCR system
(Roche, Basel, Switzerland) were used, following the manufac-
turer’s protocol. The PCR cycle conditions were as follows: 40 cy-
cles; 95 C for 30 s, 55 C for 30 s, 72 C for 30 s and a ﬁnal
extension at 72 C for 10 min. For the latter: 40 cycles; 94 C for
30 s, 60 C for 45 s, 72 C for 75 s and a ﬁnal extension at 72 C
for 5 min. The quality of the PCR was assessed by running a arbi-
trary set of PCR reactions on a gel (data not shown).
2.4. Sequencing and data analysis
For each PCR reaction, a cycle sequencing reaction was carried
out; all PCR products were sequenced using conventional Sanger
capillary sequencing technology [20]. The sequencing reactions
were performed using BigDye Terminator v3.1 Cycle Sequencing
Kit, (Applied Biosystems, Foster City, California), using the follow-
ing conditions: 35 cycles; 94 C for 40 s, 59 C for 40 s, 72 C for
100 s and a ﬁnal extension at 72 C for 8 min. The obtained se-
quences (tumor and normal) were analyzed and aligned to the fol-
lowing; exon 5: position 625–810 in NM_000546.3, exon 6:
position 811–928 in NM_000546.3, exon 7: position 924–1033 in
NM_000546.3, exon 8: position 1033–1170 in NM_000546.3. This
alignment was used to infer SNP and mutation information. We de-
ﬁned a mutation to be present when the following criteria were
met:>30% signal from an alternative base in both forward and re-verse direction. Each position where a plausible mutation was
present was examined in dbSNP [21] in order to annotate it as an
already known SNP.
2.5. Validation - pooling and cloning
In order to validate if the WGA would introduce ampliﬁcation
bias and/or allele drop-out, a pooling strategy was used to over-
come the lack of sufﬁcient amounts of sample DNA. Two pools
were generated using the cancer samples; one containing equal
amounts of unampliﬁed genomic DNA from all 123 cancer samples
and a corresponding pool using the WGA DNA from the same set of
samples. The purpose of this was to determine how many of the
mutations detected from the amplicon sequencing of individual
samples that are represented in each pool. We focused our analysis
on exon 7 since it displayed the highest frequency of mutations
among the four analyzed exons.
Exon 7 of the two pools were ampliﬁed using AmpliTaq Gold kit
(Applied Biosystems, Foster City, California), using the following
PCR cycling conditions: 40 cycles; 95 C for 30 s, 55 C for 30 s,
72 C for 30 s and a ﬁnal extension at 72 C for 10 min. After ampli-
ﬁcation, the PCR products were cloned into Escherichia coli
(pJET1.2/blunt Cloning Vector, CloneJET™ PCR Cloning Kit, Fermen-
tas International Inc., Burlington, Canada) to allow quantitative
determination of the mutation frequency.
To assess what level of redundancy was necessary to recover all
mutations found in the individually sequenced exon 7, colonies
were picked from each pool to reach a coverage of P10x. A total
of 1800 individual colonies were picked and sequenced for each
pool. The sequencing reactions were performed as described
above.
2.6. Simulations
Since it is not feasible to practically detect all mutations by
cloning and sequencing PCR fragments ampliﬁed from a pool even
at very high coverage, we simulated re-sampling of the clones and
then calculated a theoretical value of minimum redundancy. The
average number of recovered mutations is calculated as a function
of coverage for unampliﬁed and ampliﬁed samples, respectively.
Non-linear curve ﬁtting (the ‘‘nls’’ function in R [22]) was used to
ﬁt saturating curves to the data points. For the unampliﬁed case,
the curve is of the form:
N = 20-(a/(coverage-b))
where N is the number of recovered mutations, a = 120 and
b = 5.95.
For the WGA case, the curve is of the form
N = 20⁄(1  exp(a⁄(coverage-b))
where a = 0.111 and b = 0.0528.
3. Results
3.1. Mutation detection in p53 from individual cancer biopsies
To enable a comparative analysis of the whole genome ampliﬁ-
cation (WGA) procedure we selected the tumor suppressor gene
p53, since it has been reported to be frequently mutated in lung
cancer [23]. Exons 5–8 of the p53 tumor suppressor gene were
investigated to identify the most informative region in the current
material for the comparison. Each genomic sample (tumor and nor-
mal) was ﬁrst whole genome ampliﬁed followed by PCR ampliﬁca-
tion of the selected exons. The PCR products were sequenced using
the Sanger methodology and the data was aligned to the p53 refer-
ence sequence, followed by manual mutation detection identifying
gene variants and mutations (as outlined in Fig. 1A). A mutation
Fig. 1. Experimental design and mutational spectra. (A) Experimental design. The 123 tumor and normal samples in concentrations 2–41.6 ng/ul were used for whole genome
ampliﬁcation. This was followed by PCR targeting exon 5–8 in p53. All amplicons were Sanger sequenced in a forward and reverse direction and aligned against the reference
sequence. (B) Mutation spectra for exons 5–8. The four exons targeted are schematically visualized. Mutations are shown with black arrows. The number of mutations is
shown with corresponding color, and mutations outside exons are indicated in grey.
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allele.
98% of the PCR products yielded usable sequence data resulting
in discovery of a total of 40 p53 mutations among the 123 samples,
i.e., 33% mutation frequency. The mutations were found in all
exons but the majority of mutations were found in 7 (20 of 40
mutations). Five mutations were identiﬁed outside the exon
boundaries (Fig. 1B). The identiﬁed mutations were compared to
known lung cancer variants in the IARC database (http://www-
p53.iarc.fr/). Mutation prevalence and distribution was found to
be similar to the 28.8% for exons 5–8, reported in the database
(data not shown).3.2. Mutation recovery from whole genome ampliﬁed and unampliﬁed
sample pools
To investigate if our whole genome ampliﬁcation introduces
bias or leads to random loss of mutations, a pooling strategy was
devised to circumvent the low amounts of available material.
Two equimolar pools of all 123 cancer specimens were created;
one using unampliﬁed genomic DNA and one containing a pool
of whole genome ampliﬁed genomic DNA. Exon 7 was chosen as
target region due to its relatively high mutation frequency. 14 of
the 20 mutations identiﬁed in exon 7 were non-synonymous. To
allow a quantitative estimation of the mutation frequency a clon-
ing procedure was used. PCR ampliﬁcation of exon 7 from these
pools were cloned into E.coli to facilitate sequencing of individual
samples. Over 1200 clones were analyzed corresponding to an
approximately 10x coverage for the unampliﬁed pool and over
1600 clones were analyzed from the whole genome ampliﬁed pool
corresponding to an approximately 13x coverage. Mutations were
manually detected and compared to the mutations found during
the individual sample sequencing. The number of mutations recov-
ered was 13/20 and 16/20 from the unampliﬁed and WGA pools,
respectively.
Plotting the number of times each mutation was detected in the
pools reveals similarities in the mutation detection distribution.
For the most abundant mutations, similar patterns were observedin the unampliﬁed and WGA pools, however, mutations with a low
frequency were exclusively detected in the WGA pool. Of the six
synonymous mutations identiﬁed in the individual sequencing, 3
were observed in both unampliﬁed and WGA pools, and one of
the 3 was heterozygous in the WGA pools. Two additional muta-
tions were found homozygous, exclusively observed in the WGA
pools. (Supplementary Table S2). This suggests that WGA bias is
limited for these selected regions, given such low amounts of start-
ing material (Fig. 2).3.3. Investigation of the effects of sequence coverage on mutation
recovery
To determine how the different levels of sequence coverage af-
fect mutation detection in the two different DNA pools, we simu-
lated how many mutations would be recovered at different levels
of sequence coverage. For a more reliable estimation, we randomly
selected the mutation results from one PCR plate (96 sequences) at
a time in an additive manner to make a cumulative curve of muta-
tions detected as a function of coverage (by counting number of
plates analyzed). This procedure was repeated 100 times both for
the unampliﬁed and WGA samples. The obtained data points for
the average of 100 simulated runs were plotted with conﬁdence
intervals and a saturating curve was ﬁtted to them (Fig. 3A). Given
these data points and the corresponding ﬁtted curves, we extrapo-
lated to estimate the average number of recovered mutations as a
function of sequencing coverage (Fig. 3B).
Since the functions of the curves are saturated and approaches
the limit value of 20 mutations asymptotically, it is per deﬁnition
impossible to reach the corresponding coverage. To circumvent
this issue, values for recovering 80% (16 mutations) or 90% (18
mutations) of the 20 total mutations were estimated. We found
that a theoretical coverage of at least 11.4x was needed to recover
80% of the mutations (detected in the ﬁrst part of this study) when
looking at the WGAmaterial, as opposed to approximately 18.2x in
the unampliﬁed DNA. The corresponding values for 90% mutation
recovery are 16.2x and 41.0x coverage for the WGA and unampli-
ﬁed pools, respectively. See Fig. 1(A and B) in the supplementary
Fig. 2. Exon 7 mutations recovered from unampliﬁed and WGA pools. A summary of the mutations found in exon 7 is visualized by the frequency of each mutation,
normalized with respect to coverage. Mutation frequency for unampliﬁed pool is shown in dark green and WGA pool in purple. It can be observed that the mutation
frequencies follow a similar pattern for the unampliﬁed and WGA pools. This suggests that WGA is working well on this material, even with very low amounts of starting
material.
Fig. 3. Simulations and ﬁtted curves of resampling. (A) Average number of recovered mutations are plotted as a function of coverage for unampliﬁed and WGA samples after
100 rounds of random shufﬂing of the original samples. Mean values and 95% conﬁdence intervals are indicated with bars. (B) Extrapolations of the observed data in (A)
where theoretical coverage for a speciﬁc number of mutations can be estimated.
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ﬁndings.
4. Discussion
Tumor biopsies are usually available in very limited quantities;
however, DNA consuming genomic analysis platforms are todayadding vital information to cancer research and are starting to be
used in cancer diagnostics. Furthermore, samples are often distrib-
uted to multiple sites that have specialized in different analysis
tools. Thus ampliﬁcation of genomic DNA from very limited quan-
tities is of critical importance to enable thorough genetic investiga-
tions and sample distribution for independent site-speciﬁc
conﬁrmation of ﬁndings.
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the p53 exons using a WGA approach based on multiple displace-
ment ampliﬁcation of 123 tumor normal paired samples. Our data
supports the common view that p53 is a frequent target for muta-
tions in lung cancer and that most mutations identiﬁed are only
present in one or a few individuals. Moreover, the mutation prev-
alence in exons 5–8 found in this study is comparable to mutations
reported in the database (http://www-p53.iarc.fr/).
Whole genome ampliﬁcation has been used in a number of
studies, but there has been a controversy related to bias and allele
drop out resulting in alternative interpretations. Here we suggest
that WGA ampliﬁes genomic regions without signiﬁcant bias or
genome loss substantiated by a direct overlap between mutation
distribution found in unampliﬁed material and corresponding
WGA material. Interestingly, when exploring bias from the whole
genome ampliﬁcation, it was noticed that a larger portion of the
mutations at low frequency in the pool were found in WGA mate-
rial as compared to the original unampliﬁed samples. A plausible
explanation for this is that it is difﬁcult to achieve an even repre-
sentation of all samples in the pool when using minuscule amounts
of starting material. After whole genome ampliﬁcation the relative
concentration distribution is more even among the samples and
WGA can therefore serve as an approach to normalize between
samples if a pooling strategy is employed such as in screening of
mutations in larger population cohort.
Based on our simulations, we did not observe signiﬁcant sample
dropout in our WGA pool. This is of high importance when
approaching analysis on a single cell level, where there is always
a risk of DNA loss, and thus genomic regional loss, during sample
handling. A theoretical coverage of approximately 41x is needed
to recover 90% of the mutations in the original samples, whereas
only about 16x is sufﬁcient for the WGA pool. This is in accordance
with previously published results [24].
With the advent of genome sequencing as a clinical diagnostics
method, the importance of unbiased WGA is becoming more
important. It will be valuable in the ﬁeld of cancer treatment with
the possibility to perform several important quality controls, as a
result of accurate DNA ampliﬁcation. We believe this study sheds
light on the performance of this method.
The tumor suppressor gene p53 has been extensively studied
since its discovery, and plays an important role in several cancers,
including lung cancer. We present the mutation spectra of exons
5–8 in p53 from lung cancer biopsies and show that applying
WGA on the samples does not affect the composition of variations,
validated by comparison with the p53 database from IARC and
comparison with unampliﬁed material. Not surprisingly, our re-
sults show that the method described here aids in the detection
of individual mutations in pools of patients. There is no deﬁnite
number of minimum coverage for mutation detection, however,
it is mentioned that at least 10x is required for some software
[25] and 25x for a 50% false positive error rate degradation in per-
formance metrics (454 sequencing) [26]. In conclusion, whole
genome ampliﬁcation is a valuable tool when dealing with small
samples, and can be used without negotiating genetic
composition.
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